2Saag KG,Teng GG,Patkar NM,et al.American College ofRheumatology 2008 recommendations for the use of nonbiologicand biologic disease-modifying antirheumatic drugs in rheumatoidarthritis[J].Arthritis Rheum,2008,59(6):762-784.
3Smolen JS,Landewe R,Breedveld FC,et al.EULAR recommen-dations for the management of rheumatoid arthritis with syntheticand biological disease-modifying antirheumatic drugs[J].AnnRheum Dis,2010,69(6):964-975.
4Arnett FC,Edworthy SM,Bloch DA,et al.The American Rheuma-tism Association 1987 revised criteria for the classification of rheuma-toid arthritis[J].Arthritis Rheum,1988,31(3):315-324.
5Weinblatt ME,Reda D,Henderson W,et al.Sulfasalazine treat-ment for rheumatoid arthritis:a metaanalysis of 15 randomized tri-als[J].J Rheumatol,1999,26(10):2123-2130.
6Cronstein BN.Therapeutic cocktails for rheumatoid arthritis:themixmaster’s guide[J].Arthritis Rheum,2004,50(7):2041-2043.
7Jansen G,van der Heijden J,Oerlemans R,et al.Sulfasalazine isa potent inhibitor of the reduced folate carrier:implications forcombination therapies with methotrexate in rheumatoid arthritis[J].Arthritis Rheum,2004,50(7):2130-2139.
8O’Dell JR,Leff R,Paulsen G,et al.Treatment of rheumatoidarthritis with methotrexate and hydroxychloroquine,methotrexateand sulfasalazine,or a combination of the three medications:results of a two-year,randomized,double-blind,placebo-controlled trial[J].Arthritis Rheum,2002,46(5):1164-1170.
9Landewe RB,Boers M,Verhoeven AC,et al.COBRA combina-tion therapy in patients with early rheumatoid arthritis:long-termstructural benefits of a brief intervention[J].Arthritis Rheum,2002,46(2):347-356.
10Choy EH,Smith C,Dore CJ,et al.A meta-analysis of the effica-cy and toxicity of combining disease-modifying anti-rheumaticdrugs in rheumatoid arthritis based on patient withdrawal[J].Rheumatology(Oxford),2005,44(11):1414-1421.
